Demand For Vaccines Research Articles

Unvaccinated and left out: The mismatch of vaccine supply and demand during COVID‐19 as a source of interpersonal and societal exclusion

AbstractAt the beginning of the COVID‐19 vaccination campaign, many countries faced a mismatch between the demand and supply of vaccines. Particularly in countries where different rights were granted to vaccinated and unvaccinated individuals, this situation may have fostered what we here refer to as policy‐induced feelings of social exclusion. Using data from Germany in spring 2021, we investigate how individuals’ vaccination status related to feelings of (1) being excluded by others (interpersonal level) and (2) being excluded by the government (societal level) at a time when vaccinated and unvaccinated individuals had different rights. We find that being unvaccinated is associated with feeling excluded by others and by the government and that individuals generally report higher levels of exclusion by the government than by other people. These findings have important implications for policymakers not only in times of a pandemic but in light of major crises more generally.

Optimization for vaccination demand allocation and distribution routes in pandemics based on a hierarchy decision model

Vaccination plays a significant role in interrupting the spread of pandemics, the process of moving the vaccine from the distribution center (DC) through the vaccination station and ultimately to the consumer involves many decisions. Which vaccination stations are open each day, how to allocate demand residents to the open stations, how many medical personnel to arrange at the open stations and the route of refrigerated vehicles to deliver vaccines to the open stations are issues that need to be addressed in this process. To improve the efficiency of vaccination and vaccine delivery during the actual vaccination scheduling process and to reduce the total cost, this study constructs two levels to describe the above problems and proposes a hierarchical decision mixed-integer linear program (MILP) that combines vaccine delivery and vaccination that jointly addresses the problems involved in both hierarchies. A case study of the COVID-19 vaccine administered at the Center for Disease Control and Prevention (CDC) in Hongshan District, Wuhan City, China, is then given to demonstrate the feasibility of the MILP and to highlight the managerial implications. It was found that opening more vaccination stations could reduce vaccination travel costs for the demand communities, opening a reasonable number of stations and rationally allocating the demand communities to these stations could reduce the costs of the whole system. This model also provides guidance for the CDC to address similar problems and has the potential to assist in the scheduling of public medical materials.

Health workers vaccination: Experience and lessons learned from Costa Rica

ObjectiveTo describe the decision-making processes, enablers, challenges and lessons learned in Costa Rica for implementing a sustained and multi-pronged approach in health workers vaccination (HW). MethodsA retrospective descriptive analysis was conducted by searching published and grey literature, including scientific publications, legislation, decrees, policies, manuals, technical reports, and platforms used for data register and coverage monitoring. Key informants from the Ministry of Health (MoH), the Costa Rican Social Security Fund (CCSS) were interviewed representing national, subnational and local levels; as well as members of the National Technical Advisory Group (NITAG) and the private sector. Collected data were transcribed and categorized by the following specific topics using a thematic content analysis approach: decision making process, pre-service screening, vaccination for current HWs and engagement with the private sector. Major findings were discussed and organized into enablers, challenges and lessons learned. ResultsDecision making processes to establish the vaccination strategies and schedules in Costa Rica were based on the epidemiological trends of vaccine-preventable diseases (VPDs) and cost analysis. Risk assessment and feasibility considerations determined that some vaccines such as hepatitis B, varicella and influenza, were first introduced in HWs and then were expanded to other target populations. These decisions were approved by the NITAG as the advisory technical advisory group of the MoH. Main enablers identified were: high level and sustained political will, decisions based on data analysis and feasibility considerations, HWs knowledge and high vaccine acceptance and demand. Challenges were related to effective coverage monitoring, and private sector engagement. ConclusionsThe Costa Rican experience provides lessons learned that can be leveraged by other countries to strengthen HWs vaccination strategies at regional and global levels.

REVIEW ON INDIAN REGULATORY REQUIREMENTS OF CLINICAL TRIALS ON COVID VACCINES

COVID-19 is an infectious disease caused by a coronavirus strain that was discovered in December 2019 in Wuhan city,China. Corona viruses are a type of virus that causes common colds, MERS (Middle East Respiratory Syndrome), SARS(Severe Acute Respiratory Syndrome) and other illnesses. After the United States and Brazil, India has risen to third placein the world in terms of the number of COVID-19 cases. To protect humans from the disease, a race among vaccinedevelopers around the world has begun, with hundreds of COVID-19 vaccine candidates in various stages of clinicaltrials. On January 16, 2021, India's government began offering free COVID-19 vaccinations, and as part of what isanticipated to be the world's largest immunization campaign, it is asking all of its residents to get vaccinated. FourCOVID-19 vaccines, out of the eight being tested in various phases of clinical trials in India, were created. The Indianmedicines regulator has given its approval. Covishield, the Oxford-AstraZeneca vaccine, and Covaxin, a locally producedvaccine made by Bharat Biotech, are only to be used in cases of extreme urgency. The capability of Indian producers tosupply the nation's anticipated future demand for COVID-19 vaccines has been confirmed. The initial immunisation of30 million healthcare workers can be completed with the help of the staff and cold-chain infrastructure in place prior tothe pandemic. The Indian government has acted quickly to increase the nation's capacity for vaccine production and hasalso created an effective digital system to handle and monitor all facets of vaccine administration.

Operationalizing the Centers for Disease Control and Prevention's Vaccinate With Confidence Framework During the COVID-19 Emergency Response in the United States.

In December 2020, 11 months after identifying the first laboratory-confirmed case of COVID-19 in the United States, the U.S. Food and Drug Administration authorized emergency use of two COVID-19 vaccines. To prepare the public for a large-scale vaccination campaign and build confidence in COVID-19 vaccines, the U.S. Centers for Disease Control and Prevention (CDC) funded more than 200 partners and developed a national Vaccinate with Confidence (VwC) COVID-19 framework to support Americans in their decision to get vaccinated. The evolving nature of the pandemic and highly variable confidence in vaccines across populations has resulted in many unique complexities and challenges to reaching universally high vaccination coverage. Here, we describe how 23 professional health associations and national partner organizations, focused solely on building vaccine confidence, operationalized CDC's VwC COVID-19 framework from February 2021 to March 2022. Capturing how partners deployed and adapted their activities to meet a shifting pandemic landscape, which began with high demand for vaccines that waned over time, is an important first step to understanding how this new strategy was utilized and could be implemented for future surges in COVID-19 cases and other routine immunization efforts. Going forward, evaluation of partner activities should be prioritized to capture learnings and assess VwC program effectiveness.

The US Federal Retail Pharmacy Program: Optimizing COVID-19 Vaccine Delivery Through a Strategic Public-Private Partnership.

To help achieve the initial goal of providing universal COVID-19 vaccine access to approximately 258 million adults in 62 US jurisdictions, the federal government launched the Federal Retail Pharmacy Program (FRPP) on February 11, 2021. We describe FRPP's collaboration among the federal government, US jurisdictions, federal entity partners, and 21 national chain and independent pharmacy networks to provide large-scale access to COVID-19 vaccines, particularly in communities disproportionately affected by COVID-19 (eg, people aged ≥65 years, people from racial and ethnic minority groups). FRPP initially provided 10 000 vaccination sites for people to access COVID-19 vaccines, which was increased to >35 000 vaccination sites by May 2021 and sustained through January 31, 2022. From February 11, 2021, through January 31, 2022, FRPP vaccination sites received 293 million doses and administered 219 million doses, representing 45% of all COVID-19 immunizations provided nationwide (38% of all first doses, 72% of all booster doses). This unprecedented public-private partnership allowed the federal government to rapidly adapt and scale up an equitable vaccination program to reach adults, later expanding access to vaccine-eligible children, during the COVID-19 pandemic. As the largest federal COVID-19 vaccination program, FRPP exemplifies how public-private partnerships can expand access to immunizations during a public health emergency. Pharmacies can help meet critical national public health goals by serving as convenient access points for sustained health services. Lessons learned from this effort-including the importance of strong coordination and communication, efficient reporting systems and data quality, and increasing access to and demand for vaccine, among others-may help improve future immunization programs and support health system resiliency, emphasizing community-level access and health equity during public health emergencies.

Evolution of preferences for COVID-19 vaccine throughout the pandemic – The choice experiment approach

In this study, we employ a choice experiment to study individual preferences for COVID-19 vaccines in the US. A unique characteristic of the microdata (N = 5671) is that the survey was conducted in five distinct waves from October 2020 to October 2021. Because of this dynamic feature, it is possible to control for evolving pandemic conditions such as the number of COVID-19 active cases, vaccination uptake, and the frequency of Google searches related to the vaccines. Furthermore, we employ a hybrid choice model to incorporate respondents' attitudes related to their perceived vulnerability to diseases, as well as their perceived health status. The hybrid choice model was extended to incorporate latent classes as well as random effects. We find that the rate of vaccinated individuals in the population actually increases the probability of vaccine hesitancy, and therefore may discourage people to get vaccinated. This may be evidence of free-riding behavior. On the other hand, the number of COVID-19 cases has a positive effect on the probability of getting vaccinated, suggesting that individuals react to the pandemic conditions by taking some protective measures. Google trend data do not seem to have a straightforward effect on the vaccination demand, but it increases consumers’ willingness to pay for several vaccine characteristics. With respect to the analyzed attitudes, we find that perceived uninfectability is a significant driver of vaccine hesitancy, probably related to the frequent “natural immunity” argument. In turn, germ aversion has a positive effect on the probability of getting vaccinated as well as on the marginal willingness to pay. Finally, health status has a limited effect on whether the individual will decide to vaccinate or not.

Exploring the Potential of a Genome-Reduced Escherichia coli Strain for Plasmid DNA Production.

The global demand for nucleic acid-based vaccines, including plasmid DNA (pDNA) and mRNA vaccines, needs efficient production platforms. However, conventional hosts for plasmid production have encountered challenges related to sequence integrity due to the presence of insertion sequences (ISs). In this study, we explored the potential of a genome-reduced Escherichia coli as a host for pDNA production. This strain had been constructed by removing approximately 23% of the genome which were unessential genes, including the genomic unstable elements. Moreover, the strain exhibits an elevated level of NADPH, a coenzyme known to increase plasmid production according to a mathematical model. We hypothesized that the combination of genome reduction and the abundance of NADPH would significantly enhance pDNA production capabilities. Remarkably, our results confirmed a three-fold increase in pDNA production compared to the widely employed DH5α strain. Furthermore, the genome-reduced strain exhibited heightened sensitivity to various antibiotics, bolstering its potential for large scale industrial pDNA production. These findings suggest the genome-reduced E. coli as an exciting candidate for revolutionizing the pDNA industry, offering unprecedented efficiency and productivity.

Integrated Green Lean Six Sigma-Industry 4.0 approach to combat COVID-19: from literature review to framework development

PurposeThe coronavirus (COVID-19) pandemic has led to a surge in demand for health-care facilities, medicines, vaccines and other health-care items. The purpose of this study is to investigate different facets of integrated Green Lean Six Sigma and Industry 4.0 approach in the context of COVID-19 for better healthcare management. Integrating Green Lean Six Sigma (GLSS) and Industry 4.0 (I4.0) has the potential to meet the modern demand of health-care units and also leads to improving the quality of inpatient care with better safety, hygiene and real-time diagnoses. A systematic review has been conducted to determine the tools/techniques, challenges, application areas and potential benefits for the adoption of an integrated GLSS-I4.0 approach within health-care facilities from the perspective of COVID management. Further, a conceptual framework of integrated GLSS-I4.0 has been proposed for better COVID management.Design/methodology/approachTo conduct the literature review, the authors used the preferred reporting items for systematic reviews and meta-analysis and covers relevant papers from the arrival of COVID-19. Based on the systematic understanding of the different facets of the integrated GLSS-I4.0 approach and through insights of experts (academicians and health-care personnel), a conceptual framework is proposed to combat COVID-19 for better detection, prevention and cure.FindingsThe systematic review presented here provides different avenues to comprehend the different facets of the integrated GLSS-I4.0 approach in different areas of COVID health-care management. In this study, the proposed framework reveals that the Internet of Things, big data and artificial intelligence are the major constituents of I4.0 technologies that lead to better COVID management. Moreover, integration of I4.0 with GLSS aids during different stages of the COVID management, right from diagnosis, manufacture of items and inpatient and outpatient care of the affected person.Practical implicationsThis study provides a significant knowledge database to the practitioners by understanding different tools and techniques of an integrated approach for better COVID management. Moreover, the proposed framework aids to grab day-to-day information from the affected people and ensures reduced hospital stay with better space utilization and the creation of a healthy environment around the patient. This inclusive implementation of the proposed framework will enhance knowledge base in medical areas and provides different novel prospects to combat other medical urgencies.Originality/valueTo the best of the authors’ knowledge, this study is the first of its kind to review different facets of the integrated GLSS-I4.0 approach with a view of the COVID health-care perspective and provides a conceptual framework.

Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development.

Vaccination is one of the most effective strategies to control epidemics. With the deepening of people's awareness of vaccination, there is a high demand for vaccination. Hence, a flexible, rapid, and cost-effective vaccine platform is urgently needed. The baculovirus expression vector system (BEVS) has emerged as a promising technology for vaccine production due to its high safety, rapid production, flexible product design, and scalability. In this review, we introduced the development history of BEVS and the procedures for preparing recombinant protein vaccines using the BEVS platform and summarized the features and limitations of this platform. Furthermore, we highlighted the progress of the BEVS platform-related research, especially in the field of vaccine. Finally, we provided a new prospect for BEVS in future vaccine manufacturing, which may pave the way for future BEVS-derived vaccine development.

The Impact of Meso-Level Factors on SARS-CoV-2 Vaccine Early Hesitancy in the United States.

The extant literature on the U.S. SARS-CoV-2 virus indicates that the vaccination campaign was lagging, insufficient, and uncoordinated. This study uses the spatial model to identify the drivers of vaccine hesitancy (in the middle of the pandemic), one of the critical steps in creating impactful and effective interventions to influence behavioral changes now and in the future. The applied technique accounted for observed and unobserved homogeneity and heterogeneity among counties. The results indicated that political and religious beliefs, quantified by Cook's political bipartisan index and the percentage of the population affiliated with the main Christian groups, were the main drivers of the SARS-CoV-2 vaccine hesitancy. The past vaccination experience and other variables determining the demand and supply of vaccines were also crucial in influencing hesitancy. The results imply that vaccination campaigns require engaging community leaders at all levels rather than depending on politicians alone and eliminating barriers to the supply and demand of vaccines at all levels. Coordination among religious and community leaders would build a practical institutional arrangement to facilitate (rather than frustrate) the vaccination drives.

A panel dataset of COVID-19 vaccination policies in 185 countries

We present a panel dataset of COVID-19 vaccine policies, with data from 01 January 2020 for 185 countries and a number of subnational jurisdictions, reporting on vaccination prioritization plans, eligibility and availability, cost to the individual and mandatory vaccination policies. For each of these indicators, we recorded who is targeted by a policy using 52 standardized categories. These indicators document a detailed picture of the unprecedented scale of international COVID-19 vaccination rollout and strategy, indicating which countries prioritized and vaccinated which groups, when and in what order. We highlight key descriptive findings from these data to demonstrate uses for the data and to encourage researchers and policymakers in future research and vaccination planning. Numerous patterns and trends begin to emerge. For example: ‘eliminator’ countries (those that aimed to prevent virus entry into the country and community transmission) tended to prioritize border workers and economic sectors, while ‘mitigator’ countries (those that aimed to reduce the impact of community transmission) tended to prioritize the elderly and healthcare sectors for the first COVID-19 vaccinations; high-income countries published prioritization plans and began vaccinations earlier than low- and middle-income countries. Fifty-five countries were found to have implemented at least one policy of mandatory vaccination. We also demonstrate the value of combining this data with vaccination uptake rates, vaccine supply and demand data, and with further COVID-19 epidemiological data.

Post-SARS-CoV-2 Multisystemic Syndrome in the Paediatric Population of Pakistan: A Case Report

A rare life-threatening condition has been noticed in children who have been previously infected with COVID-19, involving organ inflammation, named as a multisystem inflammatory syndrome. In this study, the authors analyse a unique case, describe possibilities of disease manifestation in a particular individual, and detail different treatment options. Along with treatment and monitoring, all eligible children should be vaccinated against COVID-19. Unfortunately, due to decreased availability and increasing demand for the COVID-19 vaccine, the government in Pakistan has been led to vaccinate the general population on the basis of age group. Currently, individuals older than 12-years-old are being vaccinated, but not those who are younger. As a result, younger children have a higher chance of being infected with COVID-19 and developing multisystem inflammatory syndrome in children (MIS-C). Vaccination against the virus reduces the likelihood of COVID-19 infection. MIS-C is a rare condition found in children that might be fatal, and current evidence indicates that MIS-C occurs due to exaggerated immune response.

Perencanaan Kebijakan Persediaan Vaksin Booster Dengan Metode Continuous Review (s,S) Untuk Mengurangi Overstock Di Rumah Sakit Tentara Kota Pematangsiantar

Pematangsiantar City Army Hospital is one of the state-owned health facilities that provides booster vaccination services with 4 types of booster vaccines available, namely sinovac, astrazeneca, pfizer and moderna. The uncertain level of demand for booster vaccines causes the Pematangsiantar City Army Hospital to require booster vaccine inventory policy planning using the continuous review (s,S) method to prevent overstock which results in considerable cost expenditures. From the calculation of booster vaccine inventory control using the continuous review method (s,S), it is obtained that the total inventory cost has a significant percentage change. For the type of sinovac, the percentage change in total inventory costs reaches 92% of the total inventory costs in the existing conditions, for astrazeneca reaches 58% of the total inventory costs in the existing conditions, for pfizer reaches 60% of the total inventory costs in the existing conditions, and for moderna reaches 95% of the total inventory costs in the existing conditions. The results of the calculation of the total cost of inventory with continuous review (s,S) can provide a decrease in costs incurred by the Pematangsiantar City Army Hospital. This is because the continuous review (s,S) inventory policy minimises the cost of vaccine shortages which are quite costly.

Integrated analysis of online signals and insight generation about digital conversations on COVID-19 vaccines in Eastern and Southern Africa: a longitudinal analysis of social listening data

BackgroundDuring the COVID-19 pandemic, social listening programs across digital channels have become an integral part of health preparedness and response planning, allowing to capture and address questions, information needs, and misinformation shared by users. This study identifies key social listening trends around COVID-19 vaccines in Eastern and Southern Africa and analyses how online conversations about this issue evolved over time.MethodsA taxonomy developed and refined in collaboration with social and behaviour change teams was used to filter online conversations into nine subtopic categories. The taxonomy was applied to online content tracked in 21 countries in Eastern and Southern Africa over the period December 1, 2020—December 31, 2021. Metrics captured included volume of posts or articles and related user engagement. Qualitative analysis of content was conducted to identify key concerns, information voids and misinformation.ResultsOver 300,000 articles and posts about COVID-19 vaccines shared by users or outlets geolocated in the region were analysed. These results generated over 14 million engagements on social media and digital platforms. The analysis shows how conversations about access and availability of vaccines represented the largest share of engagement over the course of the period. Conversations about vaccine effectiveness and safety represented the second and third largest share of engagement, with peaks observed in August and November 2021. Online interest in childhood vaccination increased over time as vaccine eligibility criteria expanded in some countries in the region. Conversations mentioning mandates and certificates peaked in the last quarter of 2021, as governments as private sector entities expanded vaccine requirements.ConclusionsFindings from this study show the importance of monitoring conversation trends over time and adjust social listening data collection systems to include emerging topics. The study also points to the need to consider concerns, information voids and misinformation around effectiveness and safety of vaccines in the context of overall concern for vaccine availability and access in Eastern and Southern Africa. This is fundamental to inform social and behaviour change strategies that promote vaccine demand effectively, without increasing public frustration over vaccine availability challenges and downplaying concerns around vaccine equity.

Using community theater to improve demand for vaccination services in the Niger Delta Region of Nigeria

IntroductionDespite abundant evidence showing immunization as a lifesaving public health measure, a large proportion of Nigerian children are still not or fully vaccinated. Lack of awareness and distrust of the immunization process by caregivers are some of the reasons for poor immunization coverage which need to be addressed. This study aimed at improving vaccination demand, acceptance and uptake in Bayelsa and Rivers State, both in the Niger Delta Region (NDR) of Nigeria through a human-centered process of trust building, education and social support.MethodsA quasi-experimental intervention christened Community Theater for Immunization (CT4I) was deployed in 18 selected communities between November 2019 and May 2021 in the two states. In the intervention localities, relevant stakeholders including the leadership of the health system, community leaders, health workers and community members were engaged and actively involved in the design and performance of the theaters. The content for the theater showcased real stories, using a human-centered design (HCD) of ideation, co-creation, rapid prototyping, feedback collection and iteration. Pre- and post-intervention data on the demand and utilization of vaccination services were collected using a mixed method.ResultsIn the two states, 56 immunization managers and 59 traditional and religious leaders were engaged. Four broad themes implicating user and provider factors emerged from the 18 focus group discussions as responsible for low immunization uptake in the communities. Of the 217 caregivers trained on routine immunization and theater performances, 72% demonstrated a knowledge increase at the post-test. A total of 29 performances attended by 2,258 women were staged with 84.2% of the attendees feeling satisfied. At the performances, 270 children received vaccine shots (23% were zero-dose). There was a 38% increase in the proportion of fully immunized children in the communities and 9% decline in the proportion of zero-dose children from baseline.ConclusionBoth demand- and supply-side factors were identified as responsible for poor vaccination in the intervention communities. Our intervention demonstrates that caregivers will demand immunization services if they are engaged through community theater using a human-centered design (HCD). We recommend a scaling up of HCD to address the challenge of vaccine hesitancy.

In-silico antiviral screening of native seaweed fucoidan and its derivatives against dengue virus-2 RNA dependant RNA polymerase (RdRp)

Dengue virus (DENV) infections are a major life threat around the globe with millions of people's life is at risk. The lack of Antidengue drugs and vaccines demands lead molecules for the treatment of Dengue infections. DENV-2 RNA Dependant RNA polymerase (RdRp) was designated as the prime target because of its major role in the viral replication cycle. The purpose of the study is to isolate fucoidan and perform logical and acceptable structural modification of fucoidan for the in-silico screening against DENV for the treatment of DENV DENV-2 NS5 RdRp 6IZY RdRp enzyme was selected for the research on antiviral drugs. The sulfated polysaccharide Fucoidan was derived from brown seaweed Stoechospermum marginatum. It was subjected to acid hydrolysis to yield low molecular weight fucoidan monomer and denoted as SMFUC. SMFUC was characterized by spectroscopic studies like FTIR, NMR, and Mass spectroscopy. The SMFUC molecule was designed to yield its derivatives by the structural modification of the two 2 methyl (–CH3) and two hydroxyls (–OH) of the native fucoidan. The methyl moieties were converted to the carboxyl group, and it was further converted to its ester, amide, aldehyde, acid chloride, and ketone, the hydroxyl groups were acetylated, benzoylated, and phosphorylated. Further, Desulphate SMFUC was designed for the Insilco docking, ADMET, MMSD, and Molecular dynamic study against DENV RdRp 6IZY. SMFUC SMFUC1, SMFUC2, SMFUC3, SMFUC4, and SMFUC5 showed ligand binding affinity GLIDE scores in the range of −5.03 to −7.67541 kcal/mol against DENV-2 RdRp 6IZY amongst the native fucoidan and its derivatives. SMFUC2 showed the highest ligand binding affinity of −7.657 kcal/mol. In-silico pharmacokinetic studies of these molecules were screened using SwissADME studies and sarADMET and it was proved that these compounds were well absorbed by the GI tract and do not cross the blood–brain barrier. Simulated toxicity simulation studies proved that except for aminated, sulfated fucoidans they are non-toxic and without a metabolic enzyme inhibition activity. A simulated molecular dynamics study against the optimized fucoidans showed an RMSD score of 1.5, which indicated the ideal interaction of the fucoidan against DENV-2 RdRp. Hence, it may be concluded that seaweed fucoidan and its derivatives have high antiviral potential against DENV-2 cell wall proteins. Hence these molecules might be a lead for the emergence of antiviral drugs against DENV-2 infections.

Community-Based Approaches to Increase COVID-19 Vaccine Uptake and Demand: Lessons Learned from Four UNICEF-Supported Interventions.

Vaccination is critical to minimize serious illness and death from COVID-19. Yet uptake of COVID-19 vaccines remains highly variable, particularly among marginalized communities. This article shares lessons learned from four UNICEF interventions that supported Governments to generate acceptance and demand for COVID-19 vaccines in Zambia, Iraq, Ghana, and India. In Zambia, community rapid assessment provided invaluable real-time insights around COVID-19 vaccination and allowed the identification of population segments that share beliefs and motivations regarding COVID-19 vaccination. Findings were subsequently used to develop recommendations tailored to the different personas. In Iraq, a new outreach approach (3iS: Intensification of Integrated Immunization) utilized direct community engagement to deliver health messages and encourage service uptake, resulting in over 4.4 million doses of COVID-19 and routine immunization vaccines delivered in just 8 months. In Ghana, a human-centered design initiative was applied to co-develop community-informed strategies to improve COVID-19 vaccination rates. In India, a risk communication and community engagement initiative reached half a million people over six months, translating into a 25% increase in vaccination rates. These shared approaches can be leveraged to improve COVID-19 vaccination coverage and close gaps in routine immunization across diverse and marginalized communities.

한국, 미국, 유럽의 코로나19 백신 및 치료제 허가·승인 현황 비교

As demand for COVID-19 vaccines and treatments has soared, each country has applied appropriate approval/authorization system according to circumstances, such as emergency use authorization, conditional marketing approval, or other rapid procedures to introduce COVID-19 related items quickly. This study compared and analyzed the approval/authorization status of COVID-19 vaccines and treatments in Korea, the United States, and Europe. There were differences in the number and types of approved vaccines and treatments and also in the approval procedures used across countries. The United States adopted the emergency use authorization system, and Europe utilized the conditional marketing authorisation system, while Korea mainly applied conditional approval for vaccines and emergency use authorization for treatments. After initial approval in the US, Europe, most vaccines and treatments were introduced with delay in Korea. For instance, the average of Drug lag time for vaccines was about two months(61.5days). In the case of treatments, the difference between Drug lag time among items was relatively large. Considering that Korea's review period for drug approval is similar to that of the United States or Europe, it is necessary to proceed more quickly with approval applications and emergency authorization reviews in the event of other public health emergencies in the future.

Engaging Private Nursery and Primary Schools to Facilitate Catch - up Vaccination in Kosofe Local Government Area Lagos State Nigeria

Vaccination is very important to improve population health throughout life – but despite strong evidence, it is misunderstood and undervalued. Catch-up vaccination aims to provide optimal protection against disease as quickly as possible by completing a person’s recommended vaccination schedule in the shortest but most effective time frame. This descriptive cross-sectional implementation Research was designed to solve problems for Covid–19 recoveries for routine immunization program in private Nursery and primary school in Kosofe Local Government Area Lagos (School-based intervention). The sample size of 135 was adopted with purposive sampling method from the target population. All data were coded, entered, cleaned, and then analyzed using the IBM PSPP. Children that missed vaccination were tracked out more (90) and vaccinated, demand generation with the help of vaccine demand pooling in school for secondary vaccines, the awareness of vaccine-preventable diseases were created more at different schools Parents Teachers Association's meetings. Implementation Research is one of the measures and a component in the Immunization Agenda 2030 (IA 2030) designed to achieve the Life course immunization. Creating awareness and sensitization is very important in schools, especially using the power of storytelling for positive change in vaccination uptake. There are parents who can afford to pay for secondary vaccines but don't have the information and there are parents who have the information but can't afford to pay for secondary vaccines due to economic hardship in Nigeria. We recommend that vaccine demand pooling in schools is championed to enable parents to afford secondary vaccines for their children. Keywords: Catch-up immunization, demand generation, life course, vaccine-preventable diseases, zerodose children.